Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
Authors
Keywords
-
Journal
Kidney International Reports
Volume 8, Issue 5, Pages 968-979
Publisher
Elsevier BV
Online
2023-02-09
DOI
10.1016/j.ekir.2023.01.041
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS
- (2022) J. Barratt et al. Kidney International Reports
- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy
- (2022) Jicheng Lv et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
- (2022) Jonathan Barratt et al. KIDNEY INTERNATIONAL
- Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis
- (2021) Lesley A. Inker et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- SGLT-2 inhibition in IgA nephropathy: the new standard of care?
- (2021) Jonathan Barratt et al. KIDNEY INTERNATIONAL
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
- (2021) David C. Wheeler et al. KIDNEY INTERNATIONAL
- Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
- (2021) Antonio M Risitano et al. Lancet Haematology
- Using GFR, Albuminuria, and Their Changes in Clinical Trials and Clinical Care
- (2021) Josef Coresh et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- IgA Nephropathy: Core Curriculum 2021
- (2021) Prapa Pattrapornpisut et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Complement activation in IgA nephropathy
- (2021) Nicholas R. Medjeral-Thomas et al. Seminars in Immunopathology
- Is IgA nephropathy the same disease in different parts of the world?
- (2021) Hong Zhang et al. Seminars in Immunopathology
- Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
- (2021) Brad H. Rovin et al. KIDNEY INTERNATIONAL
- Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals
- (2021) Lukas Muri et al. Frontiers in Immunology
- Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals
- (2021) Emma Ispasanie et al. Frontiers in Immunology
- Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
- (2021) Andrew S. Bomback et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers
- (2020) Simon A. Carter et al. Clinical Journal of the American Society of Nephrology
- Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
- (2019) Aliza Thompson et al. Clinical Journal of the American Society of Nephrology
- Small-molecule factor B inhibitor for the treatment of complement-mediated diseases
- (2019) Anna Schubart et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
- (2019) Andrew S. Levey et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Beyond “Intent‐to‐treat” and “Per protocol”: Improving assessment of treatment effects in clinical trials through the specification of an estimand
- (2019) Frank Pétavy et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
- (2017) Colin Baigent et al. KIDNEY INTERNATIONAL
- IgA nephropathy
- (2016) Kar Neng Lai et al. Nature Reviews Disease Primers
- IgA Nephropathy
- (2013) Robert J. Wyatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome-wide association study identifies susceptibility loci for IgA nephropathy
- (2011) Ali G Gharavi et al. NATURE GENETICS
- Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population
- (2011) W. Le et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Natural History of Primary IgA Nephropathy
- (2008) François C. Berthoux et al. SEMINARS IN NEPHROLOGY
- A graphical approach to sequentially rejective multiple test procedures
- (2008) Frank Bretz et al. STATISTICS IN MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now